A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT ID: NCT03462927

Last Updated: 2019-12-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-08
• Study Completion Date: 2018-08-04

Brief Summary

This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene [CAL]/betamethasone [BDP] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.

Detailed Description

The MC2-01 cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on with daily routines. In this trial, the MC2-01 cream will be compared to a marketed calcipotriene [CAL]/betamethasone dipropionate [BDP] ointment. The purpose of the trial, is to determine the pharmacokinetic parameters of MC2-01 cream and the comparator under maximum use conditions.

Conditions

Psoriasis Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MC2-01 Cream

MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).

Group Type: EXPERIMENTAL

MC2-01 Cream

Intervention Type: DRUG

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)

CAL/BDP combination

CAL/BDP ointment (w/w 0.005%/0.064%).

Group Type: ACTIVE_COMPARATOR

CAL/BDP combination

Intervention Type: DRUG

Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)

Interventions

MC2-01 Cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)

Intervention Type: DRUG

CAL/BDP combination

Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Have provided written informed consent.
• Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening.
• At Visit 1/Day 0, have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration involving scalp and body (trunk and/or limbs) that is amenable to topical treatment with a maximum of 100 g of trial medication per week.
• Have a Physician's Global Assessment [PGA] of severity of at least moderate on the trunk, limbs and/or scalp, at Visit 1/Day 0.
• Have a treatment area between 20% and 30% of the body surface area [BSA] on the trunk, limbs and/or scalp, excluding psoriatic lesions on the face, genitals, and intertriginous areas, at Visit 1/Day 0.

Exclusion Criteria

• Current diagnosis of unstable forms of psoriasis
• Other inflammatory skin disease in the treatment area
• Pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
• Planned exposure to natural or artificial sunlight
• Phototherapy and ultraviolet B radiation within 4 weeks prior to Visit 1/Baseline and during the trial;
• Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders;
• Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to Visit 1/Day 0 during the trial period.
• Planned initiation of, or changes to concomitant medication that could affect calcium metabolism during the trial;
• Planned initiation of, or changes to, concomitant estrogen therapy during the trial;
• Strong systemic cytochrome P450 3A4 (CYP 3A4) inhibitors within 4 weeks prior to Vist 1/Day 0 and during the trial period;
• Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Day 0 and during the trial period;
• Systemic treatment with biological therapies
• Initiation of, or expected changes to, concomitant medication that may affect psoriasis during the trial period;
• Depression and endocrine disorders known to affect cortisol levels or HPA axis integrity, non-nocturnal sleep patterns
• Systemic medication that suppresses the immune system within 4 weeks prior to the Visit 1/Day 0 and during the trial period;
• Clinical signs of skin infection with bacteria, viruses, or fungi;
• Known human immunodeficiency virus [HIV] infection;
• Known or suspected of hypersensitivity to any component of the test product or reference product;
• Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MC2 Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

George Han

Role: PRINCIPAL_INVESTIGATOR

Department of Dermatology, Mount Sinai Beth Israel

Locations

Lenus Research and Medical Group

Sweetwater, Florida, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

MC2-01-C3

Identifier Type: -

Identifier Source: org_study_id